drugset / Trial / NCT01527513
Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the effects of eslicarbazepine acetate on cognition in comparison with placebo as adjunctive therapy in children aged 6 to 16 years old with refractory partial-onset seizures.
Timeline
- Start
- 2010-08
- Primary completion
- 2012-03
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eslicarbazepine acetate | Unknown | 30 mg/kg | Oral |